New oral GLP-1 agonist aims to reshape chronic weight management
Nxera unveils proprietary pipeline targeting obesity and metabolic disorders
You May Also Like
Vorasidenib approved in UK for treating IDH-mutant brain tumours
September 17, 2025
Imfinzi approved for NHS use in limited-stage small cell lung cancer
September 16, 2025
SOM Biotech receives EMA backing for Huntington’s disease drug
September 16, 2025
+ There are no comments
Add yours